Wall Street analysts expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to report earnings per share of ($1.18) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings. The highest EPS estimate is ($1.17) and the lowest is ($1.18). Atara Biotherapeutics posted earnings of ($1.02) per share in the same quarter last year, which would suggest a negative year over year growth rate of 15.7%. The business is scheduled to announce its next earnings report on Thursday, November 8th.
According to Zacks, analysts expect that Atara Biotherapeutics will report full year earnings of ($4.58) per share for the current fiscal year, with EPS estimates ranging from ($4.59) to ($4.58). For the next fiscal year, analysts anticipate that the company will post earnings of ($5.12) per share, with EPS estimates ranging from ($5.19) to ($5.05). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.17).
Several equities analysts recently issued reports on ATRA shares. BidaskClub lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, June 27th. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 27th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $45.00 price objective on shares of Atara Biotherapeutics in a report on Friday, August 3rd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of “Hold” and a consensus target price of $47.80.
Shares of ATRA stock opened at $36.42 on Friday. The company has a market cap of $1.87 billion, a P/E ratio of -9.11 and a beta of 2.54. Atara Biotherapeutics has a 52-week low of $12.65 and a 52-week high of $54.45.
In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 7,800 shares of the firm’s stock in a transaction that occurred on Friday, July 27th. The shares were sold at an average price of $38.00, for a total value of $296,400.00. Following the completion of the sale, the chief executive officer now directly owns 812,613 shares in the company, valued at $30,879,294. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Joe Newell sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 30th. The shares were sold at an average price of $35.78, for a total transaction of $357,800.00. Following the completion of the sale, the insider now owns 41,858 shares of the company’s stock, valued at $1,497,679.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 93,575 shares of company stock worth $3,633,158. 10.60% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Atara Biotherapeutics in the first quarter valued at approximately $107,000. Great West Life Assurance Co. Can boosted its stake in Atara Biotherapeutics by 100.1% in the second quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 1,655 shares in the last quarter. Bank of Montreal Can acquired a new stake in Atara Biotherapeutics in the second quarter valued at approximately $180,000. Principal Financial Group Inc. acquired a new stake in Atara Biotherapeutics in the first quarter valued at approximately $214,000. Finally, Highland Private Wealth Management acquired a new stake in Atara Biotherapeutics in the second quarter valued at approximately $202,000.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Recommended Story: What is a closed-end mutual fund (CEF)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.